Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27124306 | 0.93 | ABCB1 (0.37) | ABCB1MEN1NPC1ALDH1A1MAPT | |
| SCHEMBL24140381 | 0.93 | ABCB1 (0.37) | ABCB1MEN1NPC1ALDH1A1MAPT | |
| SCHEMBL26970595 | 0.91 | PLA2G4A (0.34) | PLA2G4AFAP | |
| SCHEMBL27129269 | 0.91 | PLA2G4A (0.34) | PLA2G4AFAP | |
| SCHEMBL25832393 | 0.88 | ABCB1 (0.37) | ABCB1MEN1NPC1ALDH1A1MAPT | |
| SCHEMBL24140270 | 0.85 | ABCB1 (0.37) | ABCB1MEN1NPC1ALDH1A1MAPT | |
| SCHEMBL25829278 | 0.85 | ABCB1 (0.37) | ABCB1MEN1NPC1ALDH1A1MAPT | |
| SCHEMBL24140396 | 0.83 | ABCB1 (0.39) | ABCB1MEN1NPC1ALDH1A1MAPT | |
| SCHEMBL25832382 | 0.81 | ABCB1 (0.34) | ABCB1MEN1NPC1ALDH1A1MAPT | |
| SCHEMBL26970626 | 0.80 | FAP (0.45) | ABCB1ALDH1A1FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414775-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-12-28 | — | — | US | disclosed |
| WO-2023129518-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414775-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | SDCBP, TEK, TEKT1 | ABCB1 895/4885MEN1 1024/4885NPC1 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.